Globus Medical Inc. Class A Common Stock vs NiSource Inc Common Stock — how do they compare? Globus Medical Inc. Class A Common Stock trades at $76.58 (market cap $10.25B), while NiSource Inc Common Stock trades at $41.35 (market cap $19.90B). The key difference: NiSource Inc Common Stock is the larger of the two by market cap, and NiSource Inc Common Stock pays a 2.89% dividend while Globus Medical Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Globus Medical Inc. Class A Common Stock for 0 Days and NiSource Inc Common Stock for 6 Days on average.
| GMED | NI | |
|---|---|---|
Market Cap | $10.25B | $19.90B |
Volume | 1,108,124 | 3,295,580 |
Sector | Health | Utilities |
52-Week High | $96.82 | $49.08 |
52-Week Low | $58.33 | $39.00 |
Typical Hold Time | 0 Days | 6 Days |
Enterprise Value | $9.76B | $37.23B |
Dividend Yield | — | 2.89% |
Signals from Pluang's Aura AI — not financial advice
Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.
GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.
NiSource (NI) trades at $41.49, up 0.63% today, with a bullish technical signal and strong analyst support. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 28, 2026. Fundamentals show solid profitability with a 13.15% net income margin and a P/E of 22.07. Recent news highlights dividend declarations and institutional buying interest, though the stock faces headwinds from storm recovery costs and interest rate sensitivity.
The outlook remains positive given analyst consensus with a $49.57 price target and 73% buy ratings. Key opportunities include data center demand growth and regulatory support, while risks involve volatile cash flows, high debt levels, and potential earnings pressure from operational disruptions. Investors should weigh the stable dividend yield against execution risks in a rising rate environment.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Globus Medical, Inc. develops and manufactures medical devices for treating musculoskeletal disorders, including spine, orthopedic trauma, and neurosurgical products. It operates in US and internationally, serving surgeons and healthcare providers.
Read more on GMED →NiSource is an energy holding company whose regulated subsidiaries provide natural gas and electricity services. Its business is organized around gas distribution and electric operations in the United States.
Read more on NI →